Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KCNB2 antisense RNA 1 (KCNB2-AS1) is a long noncoding RNA (lncRNA) identified in human tissue and associated with the regulation of gene expression at the RNA level[5]. It does not encode a protein but functions to modulate gene expression, primarily by binding and regulating microRNAs such as miR-3194-3p. In cancer biology, particularly in esophageal cancer, KCNB2-AS1 is upregulated and has been shown to promote cell proliferation, invasion, and migration by upregulating the expression of glycogen phosphorylase L (PYGL) through sequestration of miR-3194-3p. Because of these properties, it is under investigation as a potential biomarker in oncology, but it is not currently considered a direct therapeutic target such as a receptor, enzyme, or transporter[2][5].
Acts as a molecular sponge or inhibitor of microRNAs (e.g., binds to miR-3194-3p); Upregulates downstream effectors (e.g., glycogen phosphorylase L [PYGL] via miR-3194-3p interaction)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KCNB2 antisense RNA 1 (KCNB2-AS1).